UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease

Science translational medicine, 2016-10, Vol.8 (360), p.360ra136

2016

Volltextzugriff (PDF)

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease

Movement disorders, 2016-09, Vol.31 (9), p.1356-1365

2016

Volltextzugriff (PDF)

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans

The Journal of pharmacology and experimental therapeutics, 2013-08, Vol.346 (2), p.219-228

2013

Volltextzugriff (PDF)

Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes

Diabetes care, 2006-02, Vol.29 (2), p.345-351

2006

Volltextzugriff (PDF)

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

Circulation (New York, N.Y.), 2002-08, Vol.106 (6), p.679-684

2002

Volltextzugriff (PDF)

A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes

Diabetes care, 2001-07, Vol.24 (7), p.1226-1232

2001

Volltextzugriff (PDF)

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Diabetes (New York, N.Y.), 2006-08, Vol.55 (8), p.2357-2364

2006

Volltextzugriff (PDF)

Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe

Diabetes (New York, N.Y.), 2004-12, Vol.53 (12), p.3193-3200

2004

Volltextzugriff (PDF)

A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes

Diabetes care, 2002-11, Vol.25 (11), p.2058-2064

2002

Volltextzugriff (PDF)

Evaluation of liver function in type 2 diabetic patients during clinical trials evidence that rosiglitazone does not cause hepatic dysfunction

Diabetes care, 2002-05, Vol.25 (5), p.815-821

2002

Volltextzugriff (PDF)

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations

International journal of neuroscience, 2017-03, Vol.127 (3), p.276-284

2017

Volltextzugriff (PDF)

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

The American journal of cardiology, 2002-11, Vol.90 (9), p.947-952

2002

Volltextzugriff (PDF)

A Diabetes Outcome Progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

Diabetes care, 2002-10, Vol.25 (10), p.1737-1743

2002

Volltextzugriff (PDF)

Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism

Kidney international, 2000-04, Vol.57 (4), p.1675-1680

2000

Volltextzugriff (PDF)

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

Journal of hypertension, 2006-10, Vol.24 (10), p.2047-2055

2006

Volltextzugriff (PDF)

Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2004-12, Vol.89 (12), p.6048-6053

2004

Volltextzugriff (PDF)

A Diabetes Outcome Progression Trial (ADOPT)

Diabetes care, 2002-10, Vol.25 (10), p.1737-1743

2002

Volltextzugriff (PDF)

Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency

Journal of clinical pharmacology, 2003-03, Vol.43 (3), p.252-259

2003

Volltextzugriff (PDF)

Effect of Patient Characteristics on Motor Function in Response to 35-50 mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson’s Disease: Results from a Phase 2b Study (P5.372)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2001-01, Vol.86 (1), p.280-288

2001

Volltextzugriff (PDF)

The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers

Clinical therapeutics, 2002-07, Vol.24 (7), p.1062-1071

2002

Volltextzugriff (PDF)

Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study

The American journal of managed care, 2005-04, Vol.11 (4), p.273-278

2005

Volltextzugriff (PDF)

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

The journal of clinical endocrinology and metabolism, 2001, Vol.86 (1), p.280-288

2001

Volltextzugriff (PDF)

Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials

Diabetes care, 2002-05, Vol.25 (5), p.815-821

2002

Volltextzugriff (PDF)

Rosiglitazone Does Not Alter the Pharmacokinetics of Metformin

Journal of clinical pharmacology, 2000-11, Vol.40 (11), p.1280-1285

2000

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans

Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe

A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes

Evaluation of liver function in type 2 diabetic patients during clinical trials evidence that rosiglitazone does not cause hepatic dysfunction

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

A Diabetes Outcome Progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes

A Diabetes Outcome Progression Trial (ADOPT)

Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency

Effect of Patient Characteristics on Motor Function in Response to 35-50 mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson’s Disease: Results from a Phase 2b Study (P5.372)

Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers

Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials

Rosiglitazone Does Not Alter the Pharmacokinetics of Metformin

Suchergebnisse filtern